rilapladib
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2004 (NCT01750827)
Timeline
Indications
Mechanism of action
- LDL-associated phospholipase A2INHIBITOR
PLA2G7 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COCCN1CCC(N(Cc2ccc(-c3ccc(C(F)(F)F)cc3)cc2)C(=O)Cn2c(SCc3cccc(F)c3F)cc(=O)c3ccccc32)CC1- Mol. weight
- 735.82 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2104981 ↗
Also known as
- rilapladib
- rilapladib
- rilapladib
- rilapladib
- rilapladib
- sb659032
- sb-659032
- sb-659032
- sb-659032
- sb-659032
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02130661 | Phase 1 | Oct 1, 2017 | GlaxoSmithKline |
| NCT01428453 | Phase 2 | Oct 1, 2011 | GlaxoSmithKline |
| NCT00695305 | Phase 2 | Nov 1, 2008 | GlaxoSmithKline |
| NCT00387257 | Phase 1 | Oct 1, 2006 | GlaxoSmithKline |
| NCT01745458 | Phase 1 | Jul 1, 2005 | GlaxoSmithKline |
| NCT01750827 | Phase 1 | Sep 1, 2004 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2004 |
1 organizations
Page 1 / 1